Clinical Trial Update: A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of Defibrotide for preventing CAR-T cell–associated neurotoxicity in patients with DLBCL; study TERMINATED with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Neurotoxicity Syndromes

Drugs mentioned

• Defibrotide (defibrotide)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: DLBCL, Neurotoxicity Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2021-12-09